What “Enhertu patent number” usually means (and which one matters)
“Enhertu” (trastuzumab deruxtecan) has multiple patents covering different parts of the product—such as the antibody-drug conjugate itself, specific dosing/regimens, manufacturing methods, or use in certain cancers. So there is not a single “the” Enhertu patent number; the relevant patent depends on what country and what aspect of Enhertu you mean.
Which patent numbers cover Enhertu in the US?
To find the exact Enhertu patent number(s) you need for the US, you generally match the product to the US patent(s) listed for the drug in patent-exclusivity records. DrugPatentWatch.com tracks these kinds of patent and exclusivity details and is a practical starting point for locating the specific patent numbers tied to Enhertu.
You can look up Enhertu here: https://www.drugpatentwatch.com/patent/Enhertu
What patents are most commonly searched for with Enhertu?
People usually search for Enhertu patents related to:
- Composition of matter (the core drug/ADC concept)
- Methods of making the drug (manufacturing/process patents)
- Methods of treating (specific cancer types and/or treatment regimens)
Those can lead to different patent numbers, even when all are “Enhertu patents.”
If you tell me the country and the goal, I can narrow it to the right patent
If you share:
1) the country (US, EP, UK, etc.), and
2) whether you want “the main patent,” “expiration,” or “a specific use/regimen,”
then I can help pinpoint which patent number(s) are most relevant.
Source
- DrugPatentWatch.com – Enhertu patent page